Literature DB >> 3718827

Antibody-guided irradiation of malignant pleural and pericardial effusions.

D Pectasides, S Stewart, N Courtenay-Luck, R Rampling, A J Munro, T Krausz, B Dhokia, D Snook, G Hooker, H Durbin.   

Abstract

Tumour-associated monoclonal antibodies (HMFG1, HMFG2 and AUA1) radiolabelled with iodine-131 were given intracavitary (intrapleurally and intrapericardially) to patients with malignant effusions. Ten out of 13 effusions (3 pericardial and 7 pleural) responded completely with no fluid reaccumulation between 3 and 18 months. No clinical or other toxicity was observed. This new method of treatment for recurrent malignant effusions is non-toxic and effective resulting in improved quality of life, and, in some cases, prolongation of survival.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3718827      PMCID： PMC2001403          DOI： 10.1038/bjc.1986.125

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  10 in total

1.  The treatment of malignant pleural effusions.

Authors:  C B Anderson; G W Philpott; T B Ferguson
Journal:  Cancer       Date:  1974-04       Impact factor: 6.860

2.  Malignant pleural disease. A radiotherapeutic approach to the problem.

Authors:  S J Strober; E Klotz; A Kuperman; N A Ghossein
Journal:  JAMA       Date:  1973-10-15       Impact factor: 56.272

3.  Antibody-guided irradiation of malignant lesions: three cases illustrating a new method of treatment. A report from the Hammersmith Oncology Group and the Imperial Cancer Research Fund.

Authors: 
Journal:  Lancet       Date:  1984-06-30       Impact factor: 79.321

4.  A simplified method of quantitating organ uptake using a gamma camera.

Authors:  M J Myers; J P Lavender; J B de Oliveira; A Maseri
Journal:  Br J Radiol       Date:  1981-12       Impact factor: 3.039

5.  Use of two epithelium-specific monoclonal antibodies for diagnosis of malignancy in serous effusions.

Authors:  A A Epenetos; G Canti; J Taylor-Papadimitriou; M Curling; W F Bodmer
Journal:  Lancet       Date:  1982-11-06       Impact factor: 79.321

6.  Intracavitary bleomycin in the management of malignant effusions: a multicenter study.

Authors:  M J Ostrowski; G M Halsall
Journal:  Cancer Treat Rep       Date:  1982-11

7.  Differentiation antigens expressed by epithelial cells in the lactating breast are also detectable in breast cancers.

Authors:  J Arklie; J Taylor-Papadimitrious; W Bodmer; M Egan; R Millis
Journal:  Int J Cancer       Date:  1981-07-15       Impact factor: 7.396

8.  Intracavitary bleomycin in the management of malignant effusions.

Authors:  W Paladine; T J Cunningham; R Sponzo; M Donavan; K Olson; J Horton
Journal:  Cancer       Date:  1976-11       Impact factor: 6.860

9.  Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril.

Authors:  P J Fraker; J C Speck
Journal:  Biochem Biophys Res Commun       Date:  1978-02-28       Impact factor: 3.575

10.  Detection of human cancer in an animal model using radio-labelled tumour-associated monoclonal antibodies.

Authors:  A A Epenetos; C C Nimmon; J Arklie; A T Elliott; L A Hawkins; R W Knowles; K E Britton; W F Bodmer
Journal:  Br J Cancer       Date:  1982-07       Impact factor: 7.640
  10 in total
  10 in total

Review 1.  Monoclonal antibodies. Future potential in cancer chemotherapy.

Authors:  C Kosmas; H Kalofonos; A A Epenetos
Journal:  Drugs       Date:  1989-11       Impact factor: 9.546

2.  Carcinomatous meningitis: antibody-guided therapy with I-131 HMFG1.

Authors:  R P Moseley; J C Benjamin; R D Ashpole; N M Sullivan; J A Bullimore; H B Coakham; J T Kemshead
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-03       Impact factor: 10.154

Review 3.  Approaches to radiolabeling of antibodies for diagnosis and therapy of cancer.

Authors:  A R Fritzberg; R W Berninger; S W Hadley; D W Wester
Journal:  Pharm Res       Date:  1988-06       Impact factor: 4.200

Review 4.  Radio-immunotherapy dosimetry with special emphasis on SPECT quantification and extracorporeal immuno-adsorption.

Authors:  S E Strand; M Ljungberg; J Tennvall; K Norrgren; M Garkavij
Journal:  Med Biol Eng Comput       Date:  1994-09       Impact factor: 2.602

5.  Immunohistochemical and immunocytochemical study of bladder carcinomas using the epithelium-specific, tumour-associated monoclonal antibodies HMFG1 and AUA1.

Authors:  E Anagnostaki; D Skarlos; N Tamvakis; P Psaropoulou; E Blana; A Bamias; S Legaki; G Aravantinos; C Deliveliotis; K Dimopoulos
Journal:  Br J Cancer Suppl       Date:  1990-07

6.  Intravesical administration of tumor-associated monoclonal antibody AUA1 in transitional cell carcinoma of the bladder: a study of biodistribution.

Authors:  J Zorzos; D V Skarlos; A A Epenetos; D Pectasides; P Koutsioumba; J Elemenoglou; A Bakiras; M Likourinas; K Dimopoulos
Journal:  Urol Res       Date:  1993

Review 7.  Radionuclide therapy revisited.

Authors:  C A Hoefnagel
Journal:  Eur J Nucl Med       Date:  1991

Review 8.  Drug-targeting by monoclonal antibodies.

Authors:  M J Embleton
Journal:  Br J Cancer       Date:  1987-03       Impact factor: 7.640

9.  Repeated antitumour antibody therapy in man with suppression of the host response by cyclosporin A.

Authors:  J A Ledermann; R H Begent; K D Bagshawe; S J Riggs; F Searle; M G Glaser; A J Green; R G Dale
Journal:  Br J Cancer       Date:  1988-11       Impact factor: 7.640

Review 10.  Radioimmunotherapy of malignancy using antibody targeted radionuclides.

Authors:  L M Cobb; J L Humm
Journal:  Br J Cancer       Date:  1986-12       Impact factor: 7.640
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.